Advanced Filters
noise

pulmonary-arterial-hypertension Clinical Trials

A listing of pulmonary-arterial-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 87 clinical trials
C Chris Wynne, MD

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults

This is the second single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with dose level ranging from 15 μg to 30 μg.

18 - 65 years of age All Phase 1
V Valerie Bloss, MS

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone

18 years of age All Phase 3
Z Zongye Cai, MD, PhD

Comparison of Sequential to Initial Combination Therapy in PAH

This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH …

18 - 80 years of age All Phase N/A
E Eszter Nora Toth, M.D.

Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vascular remodelling resulting in elevated pressures in the pulmonary artery (PA). This elevated pressure ultimately leads to fulminant right heart failure. Current therapeutic options are limited and are centred around vasodilatory medications such as phosphodiesterase-5 inhibitors and prostacyclin. While these …

18 - 70 years of age All Phase 4
C Claire E Child, DPT, MPH

PAH Exercise Study

Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.

18 years of age All Phase 3
R Rodrigo Ruano, MD, Ph.D

Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)

The purpose of this research is to gather information on the safety and effectiveness of a new procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO).

18 - 50 years of age Female Phase N/A
S Stefano Ghio, PI

PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung diseases (LFD). Main Objective To demonstrate the ability of XHALIP to improve the prognosis of PAH and LFD by reducing pulmonary …

18 years of age All Phase N/A
C Caio Fernandes, PhD

Validation of a Patient Knowledge Questionnaire for Pulmonary Hypertension

This methodological study aims to develop and validate a questionnaire named for the Assessment of Patient Knowledge in Pulmonary Arterial Hypertension. The study will be conducted in four phases: (1) questionnaire development based on guidelines and literature; (2) content validation by expert judges; (3) semantic validation with patients; and (4) …

18 years of age All Phase N/A
C Claudia Salazar, BS

129 Xenon Imaging in Patients Treated With Sotatercept

Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).

18 - 75 years of age All Phase 2
D David Ptashnik, MS

Xenon MRI Pulm Hypertension

The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

18 - 75 years of age All Phase 2

Simplify language using AI